{
  "company": "GILD",
  "sections": {
    "PART I": {
      "ITEM 1. BUSINESS": {
        "summary": "Here are the key facts from the PART I - ITEM 1. BUSINESS section of GILD's annual report in bullet points:\n\n• Gilead Sciences, Inc. operates in more than 35 countries worldwide.\n• The company has transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs.\n• In 2024, Gilead's products and collaboration products with approved indications in the U.S. included:\n  • Biktarvy (HIV-1 infection treatment)\n  • Genvoya (HIV-1 infection treatment)\n  • Descovy (HIV-1 infection treatment and PrEP indication)\n  • Odefsey (HIV-1 infection treatment)\n  • Complera/Eviplera (HIV-1 infection treatment)\n  • Symtuza (HIV-1 infection treatment)\n  • Truvada (HIV-1 infection treatment and PrEP indication)\n  • Stribild (HIV-1 infection treatment)"
      },
      "RISK FACTORS": {
        "summary": "Here are the key facts from the PART I - RISK FACTORS section in bullet points:\n\n• GILD receives a substantial portion of its revenue from sales of products for the treatment and prevention of HIV infection, which may be impacted by market share gains by competitive products or changes to the treatment paradigm.\n\n• If there are any changes to the treatment or prevention paradigm for HIV, and nucleoside-based therapeutics do not remain the preferred regimen, GILD's HIV product sales would be adversely impacted.\n\n• The company is developing novel and personalized therapies such as Yescarta or Tecartus, which create significant challenges in educating and certifying medical personnel, securing sufficient supply of medications to manage side effects, developing a robust process for engineering patient T cells, and conditioning patients with chemotherapy.\n\n• In January 2024, the FDA instituted a class labeling change for all approved CAR T-cell therapies, including a \"boxed warning\" about the possible risk of secondary T-cell malignancies."
      },
      "CYBERSECURITY": {
        "summary": "Here are the key facts from the PART I - CYBERSECURITY section of GILD's report in bullet points:\n\n• GILD uses a cross-functional and layered approach to manage material risks from cybersecurity threats.\n• The company has an enterprise risk management (ERM) program that plays a critical role in managing and addressing existing and emerging risks, including cybersecurity risks.\n• GILD assesses its cybersecurity maturity annually and implements controls such as vulnerability assessments and penetration tests as needed.\n• The company executes employee cybersecurity training and awareness programs on various key cybersecurity topics, including reporting incidents, phishing, ransomware, remote working, cloud security, privileged access, and removable media.\n• GILD engages third-party advisors to assess, validate, and enhance its cybersecurity program, which helps reduce costs, increase efficiency, improve quality, mitigate risks, and review cybersecurity strategy, trends, and threat landscape.\n• The company has a dedicated Information Security team responsible for managing and coordinating incident response efforts, which collaborates with other teams within the company to identify, analyze, and respond to cybersecurity incidents.\n• GILD uses an incident response plan (IRP) to prepare for and respond to cybersecurity incidents, which is tested in annual tabletop exercises to identify strengths and areas for improvement."
      },
      "PROPERTIES": {
        "summary": "Here are the key facts from the PART I - PROPERTIES section in bullet points:\n\n• Our corporate headquarters are located in Foster City, California.\n• We have administrative facilities in Raleigh, North Carolina; Parsippany, New Jersey; Washington, D.C.; Oceanside and Santa Monica, California; Frederick, Maryland; Philadelphia, Pennsylvania; Edmonton, Canada; Dublin, Ireland; Cambridge and Oxford, United Kingdom.\n• Our principal manufacturing facilities are located in El Segundo, La Verne, Oceanside and Santa Monica, California; Frederick, Maryland; Edmonton, Canada; Cork, Ireland; Hoofddorp, Netherlands.\n• We have global operations with offices in Europe, North America, Asia, South America, Africa, Australia, the Middle East, and other regions."
      }
    },
    "PART II": {
      "ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES": {
        "summary": "Here are the key facts extracted from PART II - ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES in bullet points:\n\n• As of February 21, 2025, GILD had approximately 1,339 stockholders of record of its common stock.\n\n• The company's common stock is traded on the Nasdaq Global Select Market under the symbol \"GILD\".\n\n• For the years ended December 31, 2024 and 2023, GILD paid quarterly dividends.\n\n• As of December 31, 2024, the company had authorized $5.0 billion in stock repurchases under its 2020 Program.\n\n• The 2020 Program allows for purchases to be made in the open market or in privately negotiated transactions, with no fixed expiration.\n\n• GILD started repurchasing shares under the 2020 Program in December 2022.\n\n• As of December 31, 2024, the company had purchased a total of [number] shares under the 2020 Program."
      },
      "MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS": {
        "summary": "Here are the key facts from the PART II - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS section, formatted as bullet points:\n\n• Gilead Sciences, Inc. has pursued and achieved breakthroughs in medicine for over three decades, with the goal of creating a healthier world for all people.\n\n• The company operates in more than 35 countries worldwide, with headquarters in Foster City, California.\n\n• Gilead's strategic ambitions include bringing 10+ transformative therapies to patients by 2030, being a biotech employer and partner of choice, and delivering shareholder value in a sustainable and responsible manner.\n\n• In 2024, the company delivered growth in HIV, Oncology, and Liver Disease product sales and continued to invest in its business and research and development pipeline through acquisitions and collaborations.\n\n• Gilead completed the New Drug Application submissions to the U.S. Food and Drug Administration (FDA) for twice-yearly lenacapavir for HIV prevention.\n\n• The results of PURPOSE 2, a Phase 3 study of twice-yearly lenacapavir for HIV prevention, showed that 99.9% of participants did not acquire HIV infection, with a 96% reduction in HIV infections compared to background HIV incidence.\n\n• Gilead received Breakthrough Therapy Designation from the FDA to Trodelvy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy."
      },
      "QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK": {
        "summary": "Here are the key facts extracted from the PART II - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK section:\n\n• GILD has operations in more than 35 countries worldwide, exposing its financial results to changes in foreign currency exchange rates and weak economic conditions in foreign markets.\n\n• Approximately 27% of GILD's product sales were denominated in foreign currencies during 2024.\n\n• As of December 31, 2024 and 2023, GILD had open foreign currency forward contracts with notional amounts of $2.9 billion and $2.5 billion, respectively.\n\n• A hypothetical 10% adverse movement in foreign currency exchange rates compared to the U.S. dollar would have resulted in a reduction in fair value of these contracts of approximately $364 million and $328 million, respectively.\n\n• GILD's senior unsecured notes have fixed interest rates, eliminating financial interest rate exposure.\n\n• The fair value of GILD's debt portfolio is exposed to fluctuations in interest rates, with the current fair value being affected by changes in market interest rates."
      },
      "ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA": {
        "summary": "Here are the key facts extracted from the PART II - ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA section in bullet points:\n\n• Gilead Sciences, Inc.'s financial statements for the years ended December 31, 2024, 2023, and 2022 have been audited by Ernst & Young LLP.\n• The auditor's opinion is that the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and cash flows for each of the three years in the period ended December 31, 2024.\n• The auditor's report was dated February 28, 2025, and expressed an unqualified opinion on the Company's internal control over financial reporting as of December 31, 2024."
      },
      "CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE": {
        "summary": "Here are the key facts from the PART II - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE section:\n\n• The audit was conducted by an independent registered public accounting firm and took place as of December 31, 2024.\n• The auditor expressed an unqualified opinion on Gilead Sciences, Inc.'s internal control over financial reporting as of December 31, 2024.\n• The auditor's responsibility is to express an opinion on the Company's internal control over financial reporting based on their audit.\n• The PCAOB standards require the auditor to plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.\n• The auditor conducted procedures such as obtaining an understanding of internal control, assessing risk, testing and evaluating design and operating effectiveness, and performing other necessary procedures."
      },
      "CONTROLS AND PROCEDURES": {
        "summary": "Here are the key facts from the PART II - CONTROLS AND PROCEDURES section in bullet points:\n\n• As of December 31, 2024, GILD's Chief Executive Officer and Chief Financial Officer concluded that the company's \"disclosure controls and procedures\" were effective.\n• The company's internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statements for external purposes in accordance with generally accepted accounting principles.\n• As of December 31, 2024, GILD's management concluded that the company's internal control over financial reporting was effective based on criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control-Integrated Framework.\n• Ernst & Young LLP has audited GILD's Consolidated Financial Statements and issued a report on the company's internal control over financial reporting as of December 31, 2024.\n• In August 2023, GILD began deploying a new enterprise resource planning system (ERP) and related systems, which required changes to the company's internal control over financial reporting."
      }
    },
    "PART III": {
      "DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE": {
        "summary": "Here are the key facts from the PART III - DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE section of GILD's annual report:\n\n• The company has a written Code of Ethics that applies to all directors and employees, including executive officers.\n• The Code of Ethics is available on the company's website at www.gilead.com in the \"Investors\" section under \"Governance - Governance Documents.\"\n• The company intends to disclose future amendments to certain provisions of the Code of Ethics within four business days following the date of the amendment.\n• The company has adopted policies and procedures, including an Insider Trading Policy, to promote compliance with insider trading laws, rules, and regulations."
      }
    },
    "PART IV": {
      "EXHIBITS AND FINANCIAL STATEMENT SCHEDULES": {
        "summary": "Here are the key facts extracted from the PART IV - EXHIBITS AND FINANCIAL STATEMENT SCHEDULES section in bullet points:\n\n• The following documents are filed as part of GILD's Annual Report on Form 10-K: Index list to Consolidated Financial Statements, Exhibits.\n• There are 26 exhibits filed with this report, including filings from Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.\n• Exhibit 12 is a filing from the fiscal year ended December 31, 2019 Annual Report on Form 10-K.\n• Exhibit 13 was filed as part of GILD's Current Report on Form 8-K on May 12, 2017.\n• Exhibit 14 was filed as part of GILD's Annual Report on Form 10-K for the fiscal year ended December 31, 2020.\n• Exhibit 15 was filed as part of GILD's Current Report on Form 8-K on May 5, 2022."
      }
    }
  },
  "metadata": {
    "parts_count": 4,
    "total_sections": 23,
    "models_used": {
      "summarization": "llama3.2",
      "embedding": "dengcao/Qwen3-Embedding-0.6B:Q8_0"
    },
    "ollama_base_url": "http://localhost:11434"
  }
}